ArticleJournal of neuro-oncology2025
Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy.Journal of clinical medicine · 2026Review
- Regulatory delay and lost opportunity in IDH-mutant low-grade glioma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Patient Preferences and Treatment Decision Drivers in IDH-Mutant Grade 2 Glioma: An International Discrete Choice Experiment.The patient · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study provides a comprehensive analysis of the real-world epidemiology of histologically assessed IDH-mutated or IDH-wildtype grade II and III gliomas in Germany between 2009 and 2021, supplemented with a literature-based approach of setting the data in the context of the WHO 2021 classification.
methodsData from the Centre for Cancer Registry Data (ZfKD) at the Robert Koch-Institute (RKI) was utilized, encompassing all incident cases of histologically (according to the WHO classification of the respective time) newly diagnosed grade II and III gliomas diagnosed between 2009 and 2021, representing a subgroup of the total number of 14,053 glioma cases (including high grade glioma). Data were supplemented with an exploratory literature review on IDH-mutation rates and epidemiology data from the German low-grade glioma (LoG-Glio) disease registry.
resultsThe tumor class distribution of newly diagnosed gliomas showed the majority being classified as grade IV glioma and only 9.0% and 9.2% as grade II or III, respectively. The incidence remained stable over the observation period. Literature data indicate mutation rates of IDH of approximately 86% in grade II and 60% in grade III gliomas diagnosed using pre-WHO-2021 criteria. Applying these proportions to 2009-2021 mean incidence cases numbers in an estimate of 459 grade 2 and 328 grade 3 IDH-mutated gliomas (combining astrocytoma and oligodendroglioma) and an incidence rate of 0.6 and 0.5 per 100.000 population for newly diagnosed IDH-mutated gliomas in Germany.
conclusionThis study gives an overview of the incidence of WHO grade 2 and grade 3 gliomas among the German population. Furthermore, this study highlights the need of molecular information being integrated into epidemiologic monitoring of gliomas to obtain more precise insights into survival and prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.